 |
19 Diseases |  |
0 Trials |
|
0 Trials |  |
28 News |  |
- | Vanihep (vaniprevir) / Merck (MSD)
Journal: Transcriptome Analyses Reveal the Aroma Terpeniods Biosynthesis Pathways of Primula forbesii Franch. and the Functional Characterization of the PfDXS2 Gene. (Pubmed Central) - Aug 30, 2023
Finally, 1-deoxy-d-xylulose 5-phosphate synthase gene of P. forbesii (PfDXS2, MK370094), the first key enzyme gene in the 2-c-methyl-d-erythritol 4-phosphate (MEP) pathway of terpenoids, was cloned and functionally verified using virus-induced gene silencing (VIGs)...This report is the first to present molecular data related to aroma metabolites biosynthesis pathways and the functional characterization of any P. forbesii gene. The data on RNA sequencing provide comprehensive information for further analysis of other plants of the genus Primula.
- | Preclinical, Journal: Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro. (Pubmed Central) - Aug 25, 2021
Acyclic PIs asunaprevir and faldaprevir had ECs of 72 and 23 μM, respectively...Viral suppression was achieved with 3- to 8-fold EC50 boceprevir or 1-fold EC50 simeprevir or grazoprevir, but not boceprevir, in combination with 0.4- to 0.8-fold EC50 remdesivir; these concentrations did not lead to viral suppression in single treatments. This study could inform development and application of protease inhibitors for optimized antiviral treatments of COVID-19.
- | grazoprevir (MK-5172) / Merck (MSD)
Preclinical, Journal: Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. (Pubmed Central) - May 29, 2021
This conundrum is resolved by demonstrating that four HCV protease inhibitor drugs, simeprevir, vaniprevir, paritaprevir, and grazoprevir inhibit the SARS CoV-2 papain-like protease (PL). HCV drugs that inhibit PL synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, increasing remdesivir's antiviral activity as much as 10-fold, while those that only inhibit M do not synergize with remdesivir.
- || Vanihep (vaniprevir) / Merck (MSD)
Clinical, PK/PD data, Journal: Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection. (Pubmed Central) - Feb 17, 2021
P1
The shape of liver FNA and CNB concentration-time profiles were comparable. In conclusion, FNA may be effective for serial tissue sampling to assess hepatic drug exposure in patients with liver disease.
- ||| Vanihep (vaniprevir) / Merck (MSD)
Enrollment change: Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (clinicaltrials.gov) - Oct 2, 2014
P2, N=95, Completed, Sponsor: Merck Sharp & Dohme Corp.
In conclusion, FNA may be effective for serial tissue sampling to assess hepatic drug exposure in patients with liver disease. N=182 --> 95
- Vanihep (vaniprevir) / Merck (MSD)
Trial initiation date: Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) (clinicaltrials.gov) - Sep 29, 2014
P1, N=3, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=182 --> 95 Initiation date: Sep 2010 --> Jan 2010
- ||||||| Vanihep (vaniprevir) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Na (clinicaltrials.gov) - Apr 3, 2014
P3, N=294, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Sep 2010 --> Jan 2010 Active, not recruiting --> Completed
- Vanihep (vaniprevir) / Merck (MSD)
Trial completion: Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) (clinicaltrials.gov) - Sep 23, 2013
P1, N=31, Completed, Sponsor: Merck
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vanihep (vaniprevir) / Merck (MSD)
Enrollment change: A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) (clinicaltrials.gov) - Jun 27, 2013
P2, N=45, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=80 --> 45
- | Vanihep (vaniprevir) / Merck (MSD)
Trial completion: A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) (clinicaltrials.gov) - Jun 27, 2013
P2, N=45, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=80 --> 45 Active, not recruiting --> Completed
- Vanihep (vaniprevir) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Vaniprevir Plus PegIntron (clinicaltrials.gov) - Apr 8, 2013
P3, N=42, Completed, Sponsor: Merck
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Vanihep (vaniprevir) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Study of Vaniprevir Plus PegIntron (clinicaltrials.gov) - Mar 14, 2013
P3, N=51, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Vanihep (vaniprevir) / Merck (MSD)
Trial completion: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) (clinicaltrials.gov) - Sep 18, 2012
P2, N=285, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vanihep (vaniprevir) / Merck (MSD)
New P1 trial: Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) (clinicaltrials.gov) - Aug 30, 2012
P1, N=31, Completed, Sponsor: Merck
- |||| Vanihep (vaniprevir) / Merck (MSD)
Trial completion: A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) (clinicaltrials.gov) - Mar 21, 2012
P2, N=90, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vanihep (vaniprevir) / Merck (MSD)
Enrollment change: Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) (clinicaltrials.gov) - Feb 27, 2012
P2, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=530 --> 0
- Vanihep (vaniprevir) / Merck (MSD)
Enrollment change: Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) (clinicaltrials.gov) - Feb 7, 2012
P1, N=3, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=530 --> 0 N=18 --> 3